21 Ophthalmology CRO and CDMO vendors

What kind of CRO work does an ophthalmology program need?

Ophthalmology outsourcing is shaped by one fact: the eye is a small, immune-privileged, hard-to-reach compartment, and almost every service has an ocular-specific version. A general tox CRO can dose a rat orally; far fewer can deliver a drug intravitreally into a rabbit eye, run an ocular PK study that samples vitreous, aqueous, and retina-choroid separately, and read out ocular irritation by a validated scoring scale. So the first thing you are buying in this indication is not generic capability, it is hands that know the eye.

On the discovery and preclinical side, the work runs through in vitro models (retinal pigment epithelium cultures, photoreceptor and ganglion-cell systems, corneal epithelial models) and into the disease models that matter for your indication: laser-induced choroidal neovascularization for wet AMD, oxygen-induced retinopathy for retinopathy of prematurity and DME-adjacent angiogenesis, ocular hypertension and optic-nerve-crush models for glaucoma, and dry-eye and uveitis models for surface and inflammatory disease. Delivery route drives a lot of this. An intravitreal biologic, a topical small molecule, a suprachoroidal injection, and a gene therapy delivered subretinally each need different formulation work, different ocular PK, and different safety readouts. Larger eyes matter for translation, which is why non-human-primate work shows up in retinal programs more than in most other therapeutic areas.

IND-enabling and clinical work carry the same ocular fingerprint. GLP ocular toxicology has to handle local tolerance, intraocular pressure, slit-lamp and fundus examination, electroretinography, and ocular histopathology read by a pathologist who knows ophthalmic tissue. On the clinical side you need a CRO with ophthalmology site networks and the reading-center relationships that ophthalmology trials live on: standardized BCVA refraction (ETDRS letters), OCT-based anatomical endpoints like central subfield thickness, fundus photography and fluorescein angiography grading, and IOP measurement done consistently across sites. For injectable products, the manufacturing side needs a CDMO that can run aseptic, sterile fill-finish for intravitreal use, where particulate control and endotoxin limits are tighter than for most other routes.

How do you choose a CRO for ophthalmology?

The logo matters less than whether the specific team has run your kind of eye program before. A group with deep wet-AMD experience may have never touched a glaucoma IOP study or a subretinal gene-therapy delivery, and ocular dosing technique is genuinely a skill that varies between hands. Put two or three vendors against the same written scope and work the checklist below. Ask for indication-specific case studies, the names and ophthalmology background of the people who would actually run the study, and reference contacts you can call.

• Therapeutic-area experience: confirm real ophthalmology depth in your exact indication (wet AMD, DME, glaucoma, dry eye, uveitis, inherited retinal disease) and your delivery route (intravitreal, topical, suprachoroidal, subretinal), not just general preclinical or clinical work.
• Relevant models and ocular technique: check they run the disease models you need (laser CNV, oxygen-induced retinopathy, ocular hypertension, dry-eye) and that staff are trained in ocular dosing, plus access to the right species, including non-human primates where retinal translation requires it.
• Ocular endpoints and instrumentation: for clinical work, confirm standardized BCVA/ETDRS refraction, OCT reading-center relationships, fundus photography and angiography grading, and consistent IOP measurement; for preclinical, confirm ERG, slit-lamp, fundoscopy, and ophthalmic histopathology.
• Regulatory track record: ask about INDs filed and ophthalmology programs taken through FDA or EMA, GLP status for the safety work, and familiarity with ocular-specific guidance and CMC expectations for intraocular products.
• Data quality and traceability: documented SOPs, masked grading where endpoints are subjective, audit-ready raw data, and reading-center standardization so an OCT or angiography readout means the same thing across sites and over time.
• Capacity and timeline: ocular specialists are a smaller pool and can be booked solid, so confirm the real queue, NHP availability if needed, and honest turnaround before you commit.
• Manufacturing fit (if applicable): for injectables, a CDMO with aseptic sterile fill-finish for ophthalmic use, particulate and endotoxin control suited to intravitreal delivery, and container-closure experience for prefilled syringes or vials.